#1 Clinical Trials Search in Europe

Study on Elranatamab for Patients with Multiple Myeloma Continuing from Previous Clinical Trials

1 1 1

What is this study about?

This clinical trial is focused on studying Multiple Myeloma, a type of cancer that affects plasma cells in the bone marrow. The treatment being used in this study is called Elranatamab, which is a solution for injection developed by Pfizer Inc. The purpose of the study is to monitor the safety of Elranatamab in participants who have previously been part of other Pfizer-sponsored studies involving this medication.

Participants in this study will continue to receive Elranatamab if they have completed a previous study and are still benefiting from the treatment. The study is designed to be open-label, meaning that both the participants and the researchers know what treatment is being administered. The study will not involve a placebo, and all participants will receive the active treatment.

Throughout the study, researchers will closely monitor participants for any side effects, including both non-serious and serious adverse events. The study aims to ensure that Elranatamab remains safe for use in treating Multiple Myeloma over an extended period. Participants will receive the treatment through subcutaneous injections, which means the medication is injected under the skin. The study is expected to continue until 2027, providing ongoing access to the treatment for those who are benefiting from it.

1 joining the study

Upon joining the study, participants must have completed a qualifying parent study and were still receiving elranatamab when the parent study ended. Participants should be experiencing clinical benefits from elranatamab as determined by the investigator.

Participants must agree to follow the contraceptive and barrier guidance provided by the study.

2 medication administration

Elranatamab is administered as a solution for injection. The route of administration is subcutaneous, meaning the injection is given under the skin.

The specific dosage, frequency, and duration of administration will be determined by the study protocol and the investigator overseeing the participant’s care.

3 monitoring and safety

The main objective of the study is to monitor the safety of elranatamab. This includes observing for any nonserious adverse events that may lead to the permanent discontinuation of the medication.

All serious adverse events (SAEs) will be recorded and assessed throughout the study duration.

4 study duration

The estimated end date for the study is March 1, 2027. Participants will continue to receive elranatamab and be monitored until this date or until the study is otherwise concluded.

Who Can Join the Study?

  • Participants must agree to follow the Contraceptive and Barrier Guidance. This means they need to use methods to prevent pregnancy during the study.
  • Participants must have completed a qualifying Parent Study. This means they were part of an earlier related study.
  • Participants must have been receiving elranatamab when the Parent Study ended. Elranatamab is a medication used in the study.
  • Participants must be getting a clinical benefit from elranatamab, as determined by the investigator. This means the medication should be helping them, according to the study doctor.
  • Both male and female participants are eligible to join the study.
  • The study includes people from vulnerable populations. This means it may include groups who need special protection or care.

Who Cannot Join the Study?

  • Patients who have a different condition than multiple myeloma cannot participate. Multiple myeloma is a type of cancer that affects certain cells in the bone marrow.
  • Patients who are not within the specified age range cannot participate. The age range is typically defined by the study.
  • Patients who are not part of the specified clinical trial group cannot participate. Clinical trial groups are categories used to organize participants based on certain characteristics.
  • Patients who are considered part of a vulnerable population cannot participate. A vulnerable population includes individuals who may have a higher risk of harm or exploitation.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Hospital Universitario De Navarra Pamplona Spain

Other Sites

Site Name City Country Status
Hopital Saint Antoine Paris France
Klinikum Chemnitz gGmbH Chemnitz Germany
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer Barcelona Spain
Centre Hospitalier Lyon Sud Pierre Benite France
Hospital Universitario 12 De Octubre Madrid Spain
Hospital Universitario Dr Peset Aleixandre Valencia Spain
Avagiatosm Ppemhecd Htmnqurg Dm Pzzll Paris France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
31.12.2027
Germany Germany
Not recruiting
31.12.2027
Spain Spain
Not yet recruiting
31.12.2027

Trial locations

Investigated drugs:

Elranatamab is a medication being studied for its effects on multiple myeloma, a type of blood cancer. In this clinical trial, the main goal is to monitor the safety of this medication in participants who have already been part of previous studies sponsored by Pfizer. Elranatamab is designed to help the immune system target and fight cancer cells more effectively.

Multiple Myeloma – Multiple myeloma is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and accumulate in the bone marrow, leading to bone damage and affecting the production of normal blood cells. As the disease progresses, it can cause bone pain, fractures, and anemia due to the reduced production of healthy blood cells. Patients may also experience high levels of calcium in the blood, kidney problems, and increased susceptibility to infections. The disease often progresses slowly, but it can become more aggressive over time.

Trial ID:
2023-505200-33-00
Protocol code:
C1071015
Trial Phase:
Therapeutic confirmatory (Phase III)

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1
    Investigated drugs:
    Norway